% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Traub:164534,
      author       = {Traub, Jan and Otto, Markus and Sell, Roxane and Homola,
                      György A and Steinacker, Petra and Oeckl, Patrick and
                      Morbach, Caroline and Frantz, Stefan and Pham, Mirko and
                      Störk, Stefan and Stoll, Guido and Frey, Anna},
      title        = {{S}erum glial fibrillary acidic protein indicates memory
                      impairment in patients with chronic heart failure.},
      journal      = {ESC heart failure},
      volume       = {9},
      number       = {4},
      issn         = {2055-5822},
      address      = {Chichester},
      publisher    = {Wiley},
      reportid     = {DZNE-2022-01083},
      pages        = {2626-2634},
      year         = {2022},
      abstract     = {Cognitive dysfunction occurs frequently in patients with
                      heart failure (HF), but early detection remains challenging.
                      Serum glial fibrillary acidic protein (GFAP) is an emerging
                      biomarker of cognitive decline in disorders of primary
                      neurodegeneration such as Alzheimer's disease. We evaluated
                      the utility of serum GFAP as a biomarker for cognitive
                      dysfunction and structural brain damage in patients with
                      stable chronic HF.Using bead-based single molecule
                      immunoassays, we quantified serum levels of GFAP in patients
                      with HF participating in the prospective
                      Cognition.Matters-HF study. Participants were extensively
                      phenotyped, including cognitive testing of five separate
                      domains and magnetic resonance imaging (MRI) of the brain.
                      Univariable and multivariable models, also accounting for
                      multiple testing, were run. One hundred and forty-six
                      chronic HF patients with a mean age of 63.8 ± 10.8 years
                      were included $(15.1\%$ women). Serum GFAP levels (median
                      246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL)
                      did not differ between sexes. In the multivariable adjusted
                      model, independent predictors of GFAP levels were age (T =
                      5.5; P < 0.001), smoking (T = 3.2; P = 0.002), estimated
                      glomerular filtration rate (T = -4.7; P < 0.001), alanine
                      aminotransferase (T = -2.1; P = 0.036), and the left atrial
                      end-systolic volume index (T = 3.4; P = 0.004). NT-proBNP
                      but not serum GFAP explained global cerebral atrophy beyond
                      ageing. However, serum GFAP levels were associated with the
                      cognitive domain visual/verbal memory (T = -3.0; P = 0.003)
                      along with focal hippocampal atrophy (T = 2.3; P =
                      0.025).Serum GFAP levels are affected by age, smoking, and
                      surrogates of the severity of HF. The association of GFAP
                      with memory dysfunction suggests that astroglial
                      pathologies, which evade detection by conventional MRI, may
                      contribute to memory loss beyond ageing in patients with
                      chronic HF.},
      keywords     = {Aged / Atrophy / Biomarkers / Female / Glial Fibrillary
                      Acidic Protein: metabolism / Heart Failure: complications /
                      Heart Failure: diagnosis / Humans / Male / Memory Disorders:
                      diagnosis / Memory Disorders: etiology / Middle Aged /
                      Prospective Studies / Brain atrophy (Other) / Chronic heart
                      failure (Other) / Cognitive decline (Other) / GFAP (Other) /
                      Glial fibrillary acidic protein (Other) / Memory dysfunction
                      (Other)},
      cin          = {AG Öckl},
      ddc          = {610},
      cid          = {I:(DE-2719)5000073},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC9288738},
      pubmed       = {pmid:35611842},
      doi          = {10.1002/ehf2.13986},
      url          = {https://pub.dzne.de/record/164534},
}